Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Net Income (2016 - 2025)

Haemonetics (HAE) has 17 years of Net Income data on record, last reported at $44.7 million in Q4 2025.

  • For Q4 2025, Net Income rose 19.24% year-over-year to $44.7 million; the TTM value through Dec 2025 reached $175.4 million, up 34.87%, while the annual FY2025 figure was $167.7 million, 42.64% up from the prior year.
  • Net Income reached $44.7 million in Q4 2025 per HAE's latest filing, up from $38.7 million in the prior quarter.
  • Across five years, Net Income topped out at $58.0 million in Q1 2025 and bottomed at -$11.0 million in Q2 2021.
  • Average Net Income over 5 years is $27.5 million, with a median of $32.1 million recorded in 2022.
  • Peak YoY movement for Net Income: tumbled 162.61% in 2021, then surged 551.32% in 2022.
  • A 5-year view of Net Income shows it stood at $14.9 million in 2021, then soared by 121.76% to $32.9 million in 2022, then dropped by 5.21% to $31.2 million in 2023, then increased by 20.15% to $37.5 million in 2024, then rose by 19.24% to $44.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income were $44.7 million in Q4 2025, $38.7 million in Q3 2025, and $34.0 million in Q2 2025.